Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MSI-H/dMMR
i
Other names:
MSI-H, Microsatellite instability - high, dMMR
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related biomarkers:
Expression
Mutation
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
pembrolizumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks (New C3)
pembrolizumab
Sensitive
:
A1
ASCO-GI 2023 - 2wk
pembrolizumab
Sensitive: A1 - Approval
ASCO-GI 2023 - 2 weeks
pembrolizumab
Sensitive
:
A1
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
regorafenib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
regorafenib
Sensitive
:
C2
ASCO-GI 2023 - 2wk
regorafenib
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
regorafenib
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Gastric Cancer
MSI-H/dMMR
Gastric Cancer
durvalumab + tremelimumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C2
ASCO-GI 2023 - 2wk
durvalumab + tremelimumab
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2023 - 2 weeks
durvalumab + tremelimumab
Sensitive
:
C2
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2wk
Immunotherapy
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
Immunotherapy
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2wk
durvalumab + tremelimumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
durvalumab + tremelimumab
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
MSI-H/dMMR
Solid Tumor
MSI-H/dMMR
Solid Tumor
pembrolizumab
Sensitive: A1 - Approval
J Clin Oncol - 3 weeks (New C3)
pembrolizumab
Sensitive
:
A1
J Clin Oncol - 3wk
pembrolizumab
Sensitive: A1 - Approval
J Clin Oncol - 3 weeks
pembrolizumab
Sensitive
:
A1
J Clin Oncol - 3 weeks - (New C3)
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Solid Tumor
MSI-H/dMMR
Solid Tumor
dostarlimab
Sensitive: A1 - Approval
dostarlimab
Sensitive
:
A1
dostarlimab
Sensitive: A1 - Approval
dostarlimab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
dostarlimab
Sensitive: A1 - Approval
dostarlimab
Sensitive
:
A1
dostarlimab
Sensitive: A1 - Approval
dostarlimab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
nivolumab
Sensitive: A1 - Approval
nivolumab
Sensitive
:
A1
MSI-H/dMMR
Biliary Tract Cancer
MSI-H/dMMR
Biliary Tract Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Gastric Cancer
MSI-H/dMMR
Gastric Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
MSI-H/dMMR
Solid Tumor
MSI-H/dMMR
Solid Tumor
tislelizumab
Sensitive: A1 - Approval
tislelizumab
Sensitive
:
A1
tislelizumab
Sensitive: A1 - Approval
tislelizumab
Sensitive
:
A1
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
tislelizumab
Sensitive: A1 - Approval
tislelizumab
Sensitive
:
A1
tislelizumab
Sensitive: A1 - Approval
tislelizumab
Sensitive
:
A1
MSI-H/dMMR
Peritoneal Cancer
MSI-H/dMMR
Peritoneal Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Esophageal Cancer
MSI-H/dMMR
Esophageal Cancer
dostarlimab
Sensitive: A2 - Guideline
dostarlimab
Sensitive
:
A2
dostarlimab
Sensitive: A2 - Guideline
dostarlimab
Sensitive
:
A2
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
dostarlimab
Sensitive: A2 - Guideline
dostarlimab
Sensitive
:
A2
dostarlimab
Sensitive: A2 - Guideline
dostarlimab
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
MSI-H/dMMR
Colon Cancer
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
CAPOX
Sensitive: A2 - Guideline
CAPOX
Sensitive
:
A2
MSI-H/dMMR
Colon Cancer
MSI-H/dMMR
Colon Cancer
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
FOLFOX
Sensitive: A2 - Guideline
FOLFOX
Sensitive
:
A2
MSI-H/dMMR
Prostate Cancer
MSI-H/dMMR
Prostate Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Fallopian Tube Cancer
MSI-H/dMMR
Fallopian Tube Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Maxillary Sinus Carcinoma
MSI-H/dMMR
Maxillary Sinus Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Penile Cancer
MSI-H/dMMR
Penile Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Endometrial Cancer
MSI-H/dMMR
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
pembrolizumab + lenvatinib
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
pembrolizumab + ipilimumab
Sensitive
:
A2
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
pembrolizumab + ipilimumab
Sensitive
:
A2
MSI-H/dMMR
Small Intestinal Carcinoma
MSI-H/dMMR
Small Intestinal Carcinoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
nivolumab + ipilimumab
Sensitive: A2 - Guideline
nivolumab + ipilimumab
Sensitive
:
A2
MSI-H/dMMR
Ovarian Cancer
MSI-H/dMMR
Ovarian Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Germ Cell Tumors
MSI-H/dMMR
Germ Cell Tumors
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
MSI-H/dMMR
Gastroesophageal Junction Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Colorectal Cancer
MSI-H/dMMR
Colorectal Cancer
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
pembrolizumab + ipilimumab
Sensitive
:
A2
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
pembrolizumab + ipilimumab
Sensitive
:
A2
MSI-H/dMMR
Rectal Cancer
MSI-H/dMMR
Rectal Cancer
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
nivolumab
Sensitive: A2 - Guideline
nivolumab
Sensitive
:
A2
MSI-H/dMMR
Neuroendocrine Tumor
MSI-H/dMMR
Neuroendocrine Tumor
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Pancreatic Adenocarcinoma
MSI-H/dMMR
Pancreatic Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Cervical Cancer
MSI-H/dMMR
Cervical Cancer
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
MSI-H/dMMR
Chordoma
MSI-H/dMMR
Chordoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login